Burke Thomas Barrett Sells 50,000 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE) CEO Burke Thomas Barrett sold 50,000 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the transaction, the chief executive officer now directly owns 63,172 shares of the company’s stock, valued at approximately $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Pulse Biosciences Stock Up 1.1 %

NASDAQ PLSE opened at $17.98 on Friday. The stock has a 50-day moving average of $17.91 and a 200 day moving average of $16.62. Pulse Biosciences, Inc. has a twelve month low of $6.59 and a twelve month high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the previous year, the firm posted ($0.19) earnings per share.

Institutional Trading of Pulse Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of PLSE. Rhumbline Advisers boosted its holdings in Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after buying an additional 1,608 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of Pulse Biosciences in the second quarter worth approximately $91,000. Bank of New York Mellon Corp increased its position in shares of Pulse Biosciences by 23.4% during the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after purchasing an additional 9,639 shares in the last quarter. Creative Planning raised its stake in Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after purchasing an additional 11,667 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new stake in Pulse Biosciences during the 3rd quarter worth $378,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Thursday, December 12th.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.